<DOC>
	<DOCNO>NCT00587327</DOCNO>
	<brief_summary>The main purpose clinical research trial evaluate effect barusiban atosiban compare placebo luteal phase uterine contraction oocyte donor supplement progesterone .</brief_summary>
	<brief_title>Effect Oxytocin Vasopressin Antagonists Uterine Contractions</brief_title>
	<detailed_description>This randomise , double-blind , parallel group , placebo-controlled , multi-centre trial . It design evaluate effect selective oxytocin antagonist ( barusiban ) mix oxytocin antagonist - vasopressin V1a antagonist ( atosiban ) uterine contraction luteal phase . Participants trial oocyte donor undergo control ovarian hyperstimulation long gonadotrophin-releasing hormone ( GnRH ) agonist protocol multiple-dose single-dose GnRH antagonist protocol , receive hCG trigger final follicular maturation undergone oocyte retrieval ( OR ) . The duration trial five day participant attend clinic three occasion : Day OR +1 ( screen ) , Day OR +2 ( randomisation dose investigational medicinal product ) , Day OR +5 ( end-of-trial ) . After screen Day OR +1 , participant initiate luteal support supplementation vaginal progesterone , continue throughout trial . On Day OR +2 , participant randomise either barusiban , atosiban placebo participant receive intravenous ( IV ) bolus follow IV infusion either barusiban , atosiban placebo approximately 4h . A mock embryo transfer perform 3h start dosing . Uterine contractility parameter assess transvaginal ultrasound . The transvaginal ultrasound recording analyse uterine contraction central independent assessor , blind treatment allocation Definitions : The frequency uterine contraction define number uterine contraction per minute . A contraction define one sequential upward downward vertical displacement endometrial / myometrial interface time . The external contractile measure mean wave amplitude mm lumenal surface . This metric measure lumenal peak troughs measurement design study relationship endometrial wave activity , manifest bulk motion uterus , versus internal contractile strength . The external contractile measure report mm/contraction.The external contractile measure quantify movement uterus whole measure lumen , i.e . motion uterus relative body . The internal contractile measure strength contraction base upon sum contraction amplitude measure anterior posterior endometrial / myometrial interface . The amplitude interface define average difference endometrial / myometrial-lumenal distance measure peak troughs endometrial / myometrial interface . The internal contractile measure report mm/contraction . The internal contractile measure quantify movement endometrium relative lumen , i.e . motion internal uterus . The total contractile measure sum external contractile measure internal contractile measure quantify total muscle movement uterus . If wave anterior posterior endometrial / myometrial interface phase endometrial motion relative lumen motion pure wave motion internal contractile measure equal zero . The total contractile measure report mm/contraction . Inter-subendometrial space measure distance anterior stratum basalis posterior stratum basalis layer mid-sagittal plane anatomic location 5 10 mm fundus . All inter-subendometrial space measurement make select clear image uterus , wait contraction pas freeze image . A linear distance measurement take anatomic landmark describe . Inter-subendometrial space calculate exist measurement use mean measurement identify endometrial-myometrial interface superior inferior surface endometrial strip arrows identify endometrial contraction place motion analysis . Inter-subendometrial space report mm</detailed_description>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Atosiban</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Participants eligible trial oocyte donor 1835 year age , undergone control ovarian hyperstimulation long GnRH agonist protocol multipledose singledose GnRH antagonist protocol , receive hCG ( ≥ 5,000 IU urinary hCG 250 μg recombinant hCG ) trigger final follicular maturation undergone oocyte retrieval yield ≥ 6 cumulusoocytecomplexes . Participants give sign informed consent , generally healthy body mass index ( BMI ) 18.529.9 kg/m2 . Participants exclude case endometriosis stage IIV uterine pathology . Participants willing intake alcoholic beverage trial , sexual intercourse trial , either maintain sexual abstinence use highly effective method contraception endoftrial till onset next menses .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>